Gloucester Pharmaceuticals
Cambridge
About Gloucester Pharmaceuticals
Gloucester Pharmaceuticals is a biopharmaceutical company owned by [Celgene](/organization/celgene) that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $137.1M
- Funding stage: M&A
- Last round: Series D (Aug 2009)
- Website: gloucesterpharma.com
- Phone: +1 617-583-1300
Industries & Categories
Biotechnology, Health Care, Medical, Oncology
Canonical: https://fsome.com/organization/gloucester-pharmaceuticals-2653489 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.